Cellumen to Profile Toxins for the U.S. Environmental Protection Agency
News Apr 10, 2007
Cellumen, Inc. has announced that it has signed a multi-year contract with the U.S. Environmental Protection Agency (EPA) to profile potential toxins.
"We are pleased to be selected to participate in the EPA's ToxCast™ program," said Dr. Kate Johnston, Vice President of Discovery Programs at Cellumen.
"The goals of this program: to better prioritize environmental chemicals while reducing costs and dependency on animal testing, are perfectly aligned with Cellumen's goals in developing cytotoxicity profiling panels. This project provides a strong opportunity to demonstrate our value for both environmental and pharmaceutical applications."
"This program is an ideal complement to a collaborative program underway with Cambridge Healthtech Associates (CHA) in which Cellumen is providing profiling results to eleven pharmaceutical companies to evaluate how cytotoxicity profiling can be best incorporated into the discovery-development pipeline," Johnston added.
The Cellumen cytotoxicity profiling method measures a full dose response for 11 cellular systems biology parameters at three time points, yielding 330 data points for each compound. Advanced informatics tools are then applied to analyze, mine and display the data to identify patterns of activity and provide insights into mechanism of action.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE